Repaglinide Export Market Intelligence: India's 41 Suppliers Shipping to 36 Countries — TransData Nexus 2026

Q: Who are the top repaglinide exporters from India?

The top repaglinide exporters from India are: 1. AUROBINDO PHARMA LTD — $3.6M (51.4% market share); 2. AUROBINDO PHARMA LIMITED — $1.8M (25.5% market share); 3. USV PRIVATE LIMITED — $883.7K (12.8% market share); 4. INTAS PHARMACEUTICALS LIMITED — $343.0K (5.0% market share); 5. MACLEODS PHARMACEUTICALS LTD — $267.7K (3.9% market share). Together they account for 98.5% of India's total repaglinide export value.

Q: What is the total export value of repaglinide from India?

The total export value of repaglinide from India is $6.9M USD, recorded across 819 shipment transactions from 41 active exporters to 36 destination countries. The average shipment value is $8.4K.

Q: Which countries import repaglinide from India?

India exports repaglinide to 36 countries worldwide. The top importing countries are: UNITED STATES (60.4% share, $4.2M), FRANCE (15.7% share, $1.1M), CANADA (7.3% share, $503.4K), VIETNAM (3.9% share, $272.7K), CROATIA (3.6% share, $246.6K). These five markets account for 90.9% of total export value.

Q: What is the HS code for repaglinide exports from India?

The primary HS code for repaglinide exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of repaglinide exports from India?

The average unit price for repaglinide exports from India is $1.54 USD per unit, with prices ranging from $0.00 to $54.95 depending on formulation, packaging, and order volume. The total market is valued at $6.9M across 819 shipments.

Q: Which ports handle repaglinide exports from India?

The primary ports for repaglinide exports from India are HYDERABAD ICD (INSNF6) (13.4% of shipments), HYDERABAD ICD (11.6% of shipments), SAHAR AIR (9.9% of shipments), HYDERABAD AIR (6.6% of shipments), SAHAR AIR CARGO ACC (INBOM4) (6.2% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of repaglinide?

India is one of the world's leading exporters of repaglinide due to its large base of 41 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports repaglinide to 36 countries, demonstrating 18% global market coverage.

Q: What certifications do Indian repaglinide exporters need?

Indian repaglinide exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import repaglinide from India?

There are 112 registered buyers importing repaglinide from India, spread across 36 countries. The repeat buyer rate is 79.5%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top repaglinide supplier from India?

AUROBINDO PHARMA LTD is the leading repaglinide exporter from India with a market share of 51.4% and total export value of $3.6M across 265 shipments. The top 5 suppliers together control 98.5% of total export value.

Suresh Sormare

Repaglinide

India Pharmaceutical Trade Intelligence

$6.9M41 Suppliers36 CountriesHS 30049099

ExportsIndia → UNITED STATES60.4%India → FRANCE15.7%

ImportsGERMANY → India$167.2M DENMARK → India$185.9K

#1 Buyer: AUROLOGISTICS LLC

Repaglinide Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Repaglinide to the World

Between 2022 and 2026, India exported $6.9M worth of repaglinide across 819 verified shipments to 36 countries — covering 18% of world markets in the Advanced Diabetes Medications segment. The largest destination is UNITED STATES (60.4%). AUROBINDO PHARMA LTD leads with a 51.4% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Repaglinide export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Repaglinide export data snapshot — $6.9M · 41 exporters · 36 countriesTransData Nexus · Indian Customs Data

Top Repaglinide Exporters from India

41 active exporters · Ranked by export value

View all 41 →

Top Repaglinide Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	AUROBINDO PHARMA LTD	$3.6M	265	6	51.4%
2	AUROBINDO PHARMA LIMITED

Top Countries Importing Repaglinide from India

36 destination markets · Ranked by import value

All 36 countries →

Top Countries Importing Repaglinide from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$4.2M	60.4%
2	FRANCE	$1.1M	15.7%
3	CANADA	$503.4K	7.3%
4	VIETNAM	$272.7K	3.9%
5	CROATIA	$246.6K	3.6%
6	MALTA	$204.4K	3.0%
7	NETHERLANDS	$90.4K	1.3%
8	GREECE	$70.4K	1.0%
9	UNITED KINGDOM	$63.2K	0.9%
10	GERMANY	$57.1K	0.8%

UNITED STATES is India's largest repaglinide export destination, absorbing 60.4% of total exports worth $4.2M. The top 5 importing countries — UNITED STATES, FRANCE, CANADA, VIETNAM, CROATIA — together account for 90.9% of India's total repaglinide export value. The remaining 31 destination countries collectively receive the other 9.1%, indicating a focused distribution strategy targeting key markets.

Who Supplies Repaglinide to India?

7 origin countries · Total import value: $167.4M

India imports repaglinide from 7 countries with a combined import value of $167.4M. The largest supplier is GERMANY ($167.2M, 9 shipments), followed by DENMARK and GREECE. All values are from Indian Customs (DGFT) import records.

Countries Supplying Repaglinide to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$167.2M	9	99.9%
2	DENMARK	$185.9K	31	0.1%
3	GREECE	$6.4K	14	0.0%
4	UNITED STATES	$2.1K	7	0.0%
5	MALTA	$1.8K	17	0.0%
6	ISRAEL	$80	6	0.0%
7	HUNGARY	$6	3	0.0%

GERMANY is the largest supplier of repaglinide to India, accounting for 99.9% of total import value. The top 5 origin countries — GERMANY, DENMARK, GREECE, UNITED STATES, MALTA — together supply 100.0% of India's repaglinide imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Repaglinide

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, repaglinide has been approved through multiple Abbreviated New Drug Applications (ANDAs). According to the FDA's Orange Book, there are 31 approved ANDAs for repaglinide, indicating a competitive generic market. Notably, Sun Pharmaceutical Industries, Inc. received approval for its ANDA on November 19, 2020. The absence of current import alerts related to repaglinide suggests compliance with FDA standards among Indian exporters. The substantial number of Indian exporters (41) underscores India's significant role in supplying repaglinide to the U.S. market.

2EU & UK Regulatory Framework

In the European Union, repaglinide is subject to marketing authorization by the European Medicines Agency (EMA). The EMA's European Public Assessment Reports (EPARs) provide detailed information on approved medicinal products, including repaglinide. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of repaglinide. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions, ensuring product quality and safety.

3WHO Essential Medicines & Global Standards

Repaglinide is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its importance in managing diabetes globally. The drug is also recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality across different markets.

4India Regulatory Classification

In India, repaglinide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, repaglinide is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations.

5Patent & Exclusivity Status

The primary patents for repaglinide have expired, leading to increased generic competition. This has facilitated the entry of multiple generic manufacturers into the market, contributing to the drug's affordability and accessibility.

6Recent Industry Developments

In June 2025, the NPPA conducted a review of antidiabetic drug prices, including repaglinide, to assess market trends and ensure fair pricing. In September 2025, the CDSCO issued updated guidelines for the bioequivalence studies of generic drugs, impacting repaglinide manufacturers seeking approval. In December 2025, the DGFT streamlined the export NOC process for pharmaceutical products, including repaglinide, to facilitate international trade.

These developments reflect the dynamic regulatory environment affecting the production, pricing, and export of repaglinide from India.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Repaglinide

Retail & reference prices across 9 markets vs. India FOB export price of $1.54/unit

Global Price Benchmark for Repaglinide across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$0.50	USD	According to the FDA's Orange Book, repaglinide is an approved generic drug, which contributes to its relatively low cost in the U.S. market.
United Kingdom	$0.55	GBP	The NHS Drug Tariff sets the reimbursement price for repaglinide, ensuring affordability for patients within the National Health Service.
Germany	$0.50	EUR	The Federal Joint Committee (G-BA) in Germany regulates drug prices, and repaglinide is listed in the Arzneimittel-Richtlinie, which influences its pricing.
Australia

Supply Chain Risk Assessment — Repaglinide

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Repaglinide, a medication used to manage type 2 diabetes, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70–80% of global KSM supply is controlled by China, making it a dominant player in the pharmaceutical raw materials market.

The reliance on Chinese KSMs introduces significant vulnerabilities into the supply chain. For instance, in September 2020, China increased the prices of key drug materials by 10–20%, impacting the cost structures of Indian pharmaceutical manufacturers. Such price fluctuations, coupled with potential export restrictions or geopolitical tensions, can disrupt the consistent supply of essential medications like Repaglinide.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates a high supplier concentration for Repaglinide exports from India. The top five exporters account for 98.5% of the total export value, with AUROBINDO PHARMA LTD alone contributing 51.4%. This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could lead to substantial disruptions in the global supply of Repaglinide.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence. However, the effectiveness of these initiatives in diversifying the supplier base for Repaglinide remains to be seen.

Access Complete Repaglinide Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 819 transactions across 36 markets.

Request Demo View Pricing

Frequently Asked Questions — Repaglinide Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top repaglinide exporters from India?

The leading repaglinide exporters from India are AUROBINDO PHARMA LTD, AUROBINDO PHARMA LIMITED, USV PRIVATE LIMITED, and 9 others. AUROBINDO PHARMA LTD leads with 51.4% market share ($3.6M). The top 5 suppliers together control 98.5% of total export value.

What is the total export value of repaglinide from India?

The total export value of repaglinide from India is $6.9M, recorded across 819 shipments from 41 active exporters to 36 countries. The average shipment value is $8.4K.

Which countries import repaglinide from India?

India exports repaglinide to 36 countries. The top importing countries are UNITED STATES (60.4%), FRANCE (15.7%), CANADA (7.3%), VIETNAM (3.9%), CROATIA (3.6%), which together account for 90.9% of total export value.

What is the HS code for repaglinide exports from India?

The primary HS code for repaglinide exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Repaglinide

Repaglinide

Top Repaglinide Exporters from India

Top Countries Importing Repaglinide from India

Who Supplies Repaglinide to India?

Quick Facts

Related Advanced Diabetes Medications

Related Analysis

Need Details?

Regulatory Landscape — Repaglinide

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Repaglinide

Supply Chain Risk Assessment — Repaglinide

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Repaglinide Trade Intelligence

Frequently Asked Questions — Repaglinide Exports from India

Who are the top repaglinide exporters from India?

What is the total export value of repaglinide from India?

Which countries import repaglinide from India?

What is the HS code for repaglinide exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of repaglinide exports from India?

Which ports handle repaglinide exports from India?

Why is India a leading exporter of repaglinide?

What certifications do Indian repaglinide exporters need?

How many buyers import repaglinide from India?

What is the market share of the top repaglinide exporter from India?

Analysis Methodology